Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
Date:5/28/2009

align these areas with our corporate goals and have taken other steps to improve cGMP compliance and quality system. It should be noted that there were no deficiencies identified during the FDA inspection in the Quality Control Laboratory which supports and tests all of our products before they are released to the market."

Mr. Movens added, "We continue to attract and hire talented individuals, to improve our operation and we continue to improve both our service levels and expand our customer base where possible. Based on our own development pipeline and the current agreements we have with Sun Pharma along with other third party developers, we believe we will continue to perform well in our industry. Though we remain hopeful, the uncertainty of the timelines associated with new approvals based on our status with the FDA limits our view on our growth in the near term. Since FDA approvals are a significant part of any generic company's growth we have determined that we will not provide any further guidance related to our top line growth. We remain confident that our basic fundamental performance over the course of Fiscal 2010 will provide sufficient disclosure to our shareholders. The recent voluntary recalls previously disclosed have had a negative impact on the Company's performance and may continue to have a negative impact in the near term. Price erosion on both manufactured and distributed products also contributed to the decline of our top line growth. We remain confident that our corrective actions in compliance and quality will ultimately let us gain back our momentum of growth that we have enjoyed over the last several years. We are fortunate to have a successful marketing platform and Sun Pharmaceutical Industries Inc.'s product line to complement our manufacturing products business."

This press release should be read in conjunction with our Annual Report on Form 10-K which will provide more detailed information on the res
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review ... fat loss program ever developed. It promises to provide users ... is no wonder after all that this has become the ... nutrition and workout fat loss program was created by Joel ... to the author of this fat loss system, the method ...
(Date:10/31/2014)... At the start of 2014, numerous ... carbon monoxide poisoning in their homes. Now, as 2015 ... family-owned, Missouri-based heating and cooling company is taking a ... start the home heating season with the assurance that ... Beginning Nov. 1, 2014, E and Q Heating and ...
(Date:10/31/2014)... Energy Textiles has recently added a ... is now available online, and Energy Textile is providing ... infrared-active athletic gear over compression gear. , The ... been signed for Under Armour to provide team gear ... years. In light of this decision, Energy Textiles contemplates ...
(Date:10/31/2014)... -- Obesity increases the risk of certain types of ... new U.S. studies show. One study of more ... increased the risk for estrogen receptor-negative and progesterone receptor-positive ... for a long time for white women, but now ... author Esther John, a senior research scientist at the ...
(Date:10/31/2014)... one out of four older Americans say that either ... unwanted medical treatment, according to the latest issue of ... Aging Report ( PP&AR ), which goes on ... when they fail to honor patients, end-of-life health care ... Illness Care: Issues and Options ," features 12 articles ...
Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Advance directives can benefit patients, families, and health care system 2
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
... for Patient-Provider Decision MakingFurther Action Needed to Ensure ... Senate today improved on a comparative effectiveness research ... $1.1 billion dollar research effort on clinical effectiveness," ... of the National Alliance for Hispanic Health, the ...
... Ringling Bros.(R) Conservation and Breeding ProgramVIENNA, Va., Jan. 27 ... Elephant Conservation (R) proudly announces the ... twenty-second birth in what has proven to be the most ... importantly, this is the first calf in the Ringling ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) ... the market closes, it will report results for the ... February 24, 2009, at 9:00 a.m. Central Time, Healthcare ... results, quarterly activities,general operations of the Company and industry ...
... has completed a new study on uric acid and C8 and ... increased uric acid is associated with higher levels of C8 and ... can cause an increase in uric acid.The Science Panel team recently ... (also known as PFOA) and C8S (also known as PFOS) in ...
... St. Jude Children,s Research Hospital and the Children,s Oncology ... leukemia (ALL) scores of inherited genetic variations that clinicians ... more effective chemotherapy for this cancer. ... rates for ALL exceed 80 percent, patient responses vary ...
Cached Medicine News:Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 4Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 5Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:C8 Science Panel Completes Uric Acid Study 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 3
(Date:10/31/2014)... , Oct. 31, 2014 Imago ... today announced a $26.5 million Series A financing ... firm founded by a team of accomplished investment ... investors participating in the round include Frazier Healthcare, ... Representatives from Clarus Ventures and Frazier Healthcare will ...
(Date:10/31/2014)... ARBOR, Mich. , Oct. 31, 2014 /PRNewswire/ ... immune modulators to treat autoimmune disease and cancer, ... of novel synthetic RORgamma agonist product candidates will ... Society for Immunotherapy of Cancer (SITC) being held ... & Convention Center, National Harbor, MD.  The poster, ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow ...
Breaking Medicine Technology:Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - ... a new 42 month follow-up study of ... evaluated symptomatic,progress of U.S. patients involved in ... 2003. Individuals in the study were assessed,for ...
... at American Association for Cancer Research ... /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, Inc. , a ... commercializing proprietary product,candidates for the treatment ... positive results from preclinical studies using ...
Cached Medicine Technology:Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 3Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 4
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
... is a simultaneous vision lens ... Through a series of front ... LifeStyle Gp delivers up to ... its multi-aspheric center-distance design works ...
Gendron ophthalmic eye surgery stretcher....
... surgical stretcher. M-701 Stretcher has a ... to 32 in., measured with a ... a high range, 28 in. to ... pad can be supplied optionally. Vinyl ...
Medicine Products: